File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies

TitleRobust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies
Authors
Keywordsnasal turbinate
COVID-19
phage display
upper respiratory tract
SARS-CoV-2
receptor binding domain
lung injury
human neutralizing antibody
Issue Date2021
Citation
Cell Host and Microbe, 2021, v. 29 n. 4, p. 551-563.e5 How to Cite?
Abstract© 2021 Elsevier Inc. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by a burst in the upper respiratory portal for high transmissibility. To determine human neutralizing antibodies (HuNAbs) for entry protection, we tested three potent HuNAbs (IC50 range, 0.0007–0.35 μg/mL) against live SARS-CoV-2 infection in the golden Syrian hamster model. These HuNAbs inhibit SARS-CoV-2 infection by competing with human angiotensin converting enzyme-2 for binding to the viral receptor binding domain (RBD). Prophylactic intraperitoneal or intranasal injection of individual HuNAb or DNA vaccination significantly reduces infection in the lungs but not in the nasal turbinates of hamsters intranasally challenged with SARS-CoV-2. Although postchallenge HuNAb therapy suppresses viral loads and lung damage, robust infection is observed in nasal turbinates treated within 1–3 days. Our findings demonstrate that systemic HuNAb suppresses SARS-CoV-2 replication and injury in lungs; however, robust viral infection in nasal turbinate may outcompete the antibody with significant implications to subprotection, reinfection, and vaccine.
DescriptionBronze open access
Persistent Identifierhttp://hdl.handle.net/10722/297318
ISSN
2023 Impact Factor: 20.6
2023 SCImago Journal Rankings: 7.760
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorZhou, Dongyan-
dc.contributor.authorChan, Jasper Fuk Woo-
dc.contributor.authorZhou, Biao-
dc.contributor.authorZhou, Runhong-
dc.contributor.authorLi, Shuang-
dc.contributor.authorShan, Sisi-
dc.contributor.authorLiu, Li-
dc.contributor.authorZhang, Anna Jinxia-
dc.contributor.authorChen, Serena J.-
dc.contributor.authorChan, Chris Chung Sing-
dc.contributor.authorXu, Haoran-
dc.contributor.authorPoon, Vincent Kwok Man-
dc.contributor.authorYuan, Shuofeng-
dc.contributor.authorLi, Cun-
dc.contributor.authorChik, Kenn Ka Heng-
dc.contributor.authorChan, Chris Chun Yiu-
dc.contributor.authorCao, Jianli-
dc.contributor.authorChan, Chun Yin-
dc.contributor.authorKwan, Ka Yi-
dc.contributor.authorDu, Zhenglong-
dc.contributor.authorLau, Thomas Tsz Kan-
dc.contributor.authorZhang, Qi-
dc.contributor.authorZhou, Jie-
dc.contributor.authorTo, Kelvin Kai Wang-
dc.contributor.authorZhang, Linqi-
dc.contributor.authorHo, David D.-
dc.contributor.authorYuen, Kwok Yung-
dc.contributor.authorChen, Zhiwei-
dc.date.accessioned2021-03-15T07:33:30Z-
dc.date.available2021-03-15T07:33:30Z-
dc.date.issued2021-
dc.identifier.citationCell Host and Microbe, 2021, v. 29 n. 4, p. 551-563.e5-
dc.identifier.issn1931-3128-
dc.identifier.urihttp://hdl.handle.net/10722/297318-
dc.descriptionBronze open access-
dc.description.abstract© 2021 Elsevier Inc. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by a burst in the upper respiratory portal for high transmissibility. To determine human neutralizing antibodies (HuNAbs) for entry protection, we tested three potent HuNAbs (IC50 range, 0.0007–0.35 μg/mL) against live SARS-CoV-2 infection in the golden Syrian hamster model. These HuNAbs inhibit SARS-CoV-2 infection by competing with human angiotensin converting enzyme-2 for binding to the viral receptor binding domain (RBD). Prophylactic intraperitoneal or intranasal injection of individual HuNAb or DNA vaccination significantly reduces infection in the lungs but not in the nasal turbinates of hamsters intranasally challenged with SARS-CoV-2. Although postchallenge HuNAb therapy suppresses viral loads and lung damage, robust infection is observed in nasal turbinates treated within 1–3 days. Our findings demonstrate that systemic HuNAb suppresses SARS-CoV-2 replication and injury in lungs; however, robust viral infection in nasal turbinate may outcompete the antibody with significant implications to subprotection, reinfection, and vaccine.-
dc.languageeng-
dc.relation.ispartofCell Host and Microbe-
dc.subjectnasal turbinate-
dc.subjectCOVID-19-
dc.subjectphage display-
dc.subjectupper respiratory tract-
dc.subjectSARS-CoV-2-
dc.subjectreceptor binding domain-
dc.subjectlung injury-
dc.subjecthuman neutralizing antibody-
dc.titleRobust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1016/j.chom.2021.02.019-
dc.identifier.pmid33657424-
dc.identifier.pmcidPMC7904446-
dc.identifier.scopuseid_2-s2.0-85101883548-
dc.identifier.hkuros323268-
dc.identifier.volume29-
dc.identifier.issue4-
dc.identifier.spage551-
dc.identifier.epage563.e5-
dc.identifier.eissn1934-6069-
dc.identifier.isiWOS:000640196800010-
dc.identifier.issnl1931-3128-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats